Michael A Gillette,Shankha Satpathy,Song Cao,Saravana M Dhanasekaran,Suhas V Vasaikar,Karsten Krug,Francesca Petralia,Yize Li,Wen-Wei Liang,Boris Reva,Azra Krek,Jiayi Ji,Xiaoyu Song,Wenke Liu,Runyu Hong,Lijun Yao,Lili Blumenberg,Sara R Savage,Michael C Wendl,Bo Wen,Kai Li,Lauren C Tang,Melanie A MacMullan,Shayan C Avanessian,M Harry Kane,Chelsea J Newton,MacIntosh Cornwell,Ramani B Kothadia,Weiping Ma,Seungyeul Yoo,Rahul Mannan,Pankaj Vats,Chandan Kumar-Sinha,Emily A Kawaler,Tatiana Omelchenko,Antonio Colaprico,Yifat Geffen,Yosef E Maruvka,Felipe da Veiga Leprevost,Maciej Wiznerowicz,Zeynep H Gümüş,Rajwanth R Veluswamy,Galen Hostetter,David I Heiman,Matthew A Wyczalkowski,Tara Hiltke,Mehdi Mesri,Christopher R Kinsinger,Emily S Boja,Gilbert S Omenn,Arul M Chinnaiyan,Henry Rodriguez,Qing Kay Li,Scott D Jewell,Mathangi Thiagarajan,Gad Getz,Bing Zhang,David Fenyö,Kelly V Ruggles,Marcin P Cieslik,Ana I Robles,Karl R Clauser,Ramaswamy Govindan,Pei Wang,Alexey I Nesvizhskii,Li Ding,D R Mani,Steven A Carr,Clinical Proteomic Tumor Analysis Consortium,Alex Webster,Alicia Francis,Alyssa Charamut,Amanda G Paulovich,Amy M Perou,Andrew K Godwin,Andrii Karnuta,Annette Marrero-Oliveras,Barbara Hindenach,Barbara Pruetz,Bartosz Kubisa,Brian J Druker,Chet Birger,Corbin D Jones,Dana R Valley,Daniel C Rohrer,Daniel Cui Zhou,Daniel W Chan,David Chesla,David J Clark,Dmitry Rykunov,Donghui Tan,Elena V Ponomareva,Elizabeth Duffy,Eric J Burks,Eric E Schadt,Erik J Bergstrom,Eugene S Fedorov,Ewa Malc,George D Wilson,Hai-Quan Chen,Halina M Krzystek,Hongwei Liu,Houston Culpepper,Hua Sun,Hui Zhang,Jacob Day,James Suh,Jeffrey R Whiteaker,Jennifer Eschbacher,John McGee,Karen A Ketchum,Karin D Rodland,Karna Robinson,Katherine A Hoadley,Kei Suzuki,Ki Sung Um,Kim Elburn,Liang-Bo Wang,Lijun Chen,Linda Hannick,Liqun Qi,Lori J Sokoll,Małgorzata Wojtyś,Marcin J Domagalski,Marina A Gritsenko,Mary B Beasley,Matthew E Monroe,Matthew J Ellis,Maureen Dyer,Meghan C Burke,Melissa Borucki,Meng-Hong Sun,Michael H Roehrl,Michael J Birrer,Michael Noble,Michael Schnaubelt,Michael Vernon,Michelle Chaikin,Mikhail Krotevich,Munziba Khan,Myvizhi Esai Selvan,Nancy Roche,Nathan J Edwards,Negin Vatanian,Olga Potapova,Pamela Grady,Peter B McGarvey,Piotr Mieczkowski,Pushpa Hariharan,Rashna Madan,Ratna R Thangudu,Richard D Smith,Robert J Welsh,Robert Zelt,Rohit Mehra,Ronald Matteotti,Sailaja Mareedu,Samuel H Payne,Sandra Cottingham,Sanford P Markey,Seema Chugh,Shaleigh Smith,Shirley Tsang,Shuang Cai,Simina M Boca,Sonya Carter,Stacey Gabriel,Stephanie De Young,Stephen E Stein,Sunita Shankar,Tanya Krubit,Tao Liu,Tara Skelly,Thomas Bauer,Uma Velvulou,Umut Ozbek,Vladislav A Petyuk,Volodymyr Sovenko,William E Bocik,William W Maggio,Xi Chen,Yan Shi,Yige Wu,Yingwei Hu,Yuxing Liao,Zhen Zhang,Zhiao Shi

Abstract:To explore the biology of lung adenocarcinoma (LUAD) and identify new therapeutic opportunities, we performed comprehensive proteogenomic characterization of 110 tumors and 101 matched normal adjacent tissues (NATs) incorporating genomics, epigenomics, deep-scale proteomics, phosphoproteomics, and acetylproteomics. Multi-omics clustering revealed four subgroups defined by key driver mutations, country, and gender. Proteomic and phosphoproteomic data illuminated biology downstream of copy number aberrations, somatic mutations, and fusions and identified therapeutic vulnerabilities associated with driver events involving KRAS, EGFR, and ALK. Immune subtyping revealed a complex landscape, reinforced the association of STK11 with immune-cold behavior, and underscored a potential immunosuppressive role of neutrophil degranulation. Smoking-associated LUADs showed correlation with other environmental exposure signatures and a field effect in NATs. Matched NATs allowed identification of differentially expressed proteins with potential diagnostic and therapeutic utility. This proteogenomics dataset represents a unique public resource for researchers and clinicians seeking to better understand and treat lung adenocarcinomas.

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1.

Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Figure 1 from Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer

Supplementary Figure S1 from Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead to PARP Inhibitor Sensitization

Supplementary Data 1 from Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors

Supplementary Figures 1-9, Supplementary Table 1 from Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib

Supplementary Figure Legends from RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer

Supplementary Figure 5 from Systems Analysis of the NCI-60 Cancer Cell Lines by Alignment of Protein Pathway Activation Modules with “-OMIC” Data Fields and Therapeutic Response Signatures

Supplementary Figure S2 from LIMD2 Is a Small LIM-Only Protein Overexpressed in Metastatic Lesions That Regulates Cell Motility and Tumor Progression by Directly Binding to and Activating the Integrin-Linked Kinase

Supplementary Figure 5 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma

A proteogenomic portrait of lung squamous cell carcinoma

Supplementary Figure S6 from Targeted Therapy of &Lt;i>tert</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Figure 6 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Figure 9 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Figure 4 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice